Jagsonpal Pharmaceuticals Valuation
| JAGSNPHARM | 213.70 17.70 7.65% |
At this time, the firm appears to be overvalued. Jagsonpal Pharmaceuticals retains a regular Real Value of USD205.15 per share. The prevalent price of the firm is USD213.7. Our model calculates the value of Jagsonpal Pharmaceuticals from evaluating the firm fundamentals such as Current Valuation of 14.71 B, return on asset of 0.0605, and Return On Equity of 0.13 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Jagsonpal Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Jagsonpal Pharmaceuticals is based on 3 months time horizon. Increasing Jagsonpal Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Jagsonpal Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Jagsonpal Stock. However, Jagsonpal Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 213.7 | Real 205.15 | Hype 213.7 | Naive 6833.7 |
The intrinsic value of Jagsonpal Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Jagsonpal Pharmaceuticals' stock price.
Estimating the potential upside or downside of Jagsonpal Pharmaceuticals Limited helps investors to forecast how Jagsonpal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Jagsonpal Pharmaceuticals more accurately as focusing exclusively on Jagsonpal Pharmaceuticals' fundamentals will not take into account other important factors: Jagsonpal Pharmaceuticals Total Value Analysis
Jagsonpal Pharmaceuticals Limited is currently forecasted to have takeover price of 14.71 B with market capitalization of 15.39 B, debt of 89.41 M, and cash on hands of 110.53 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Jagsonpal Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.71 B | 15.39 B | 89.41 M | 110.53 M |
Jagsonpal Pharmaceuticals Investor Information
About 74.0% of the company shares are held by company insiders. The company last dividend was issued on the 6th of September 2024. Jagsonpal Pharmaceuticals had 1:2 split on the 14th of October 2024. Based on the key indicators related to Jagsonpal Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Jagsonpal Pharmaceuticals Limited is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Jagsonpal Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Jagsonpal Pharmaceuticals has an asset utilization ratio of 96.14 percent. This signifies that the Company is making USD0.96 for each dollar of assets. An increasing asset utilization means that Jagsonpal Pharmaceuticals Limited is more efficient with each dollar of assets it utilizes for everyday operations.Jagsonpal Pharmaceuticals Ownership Allocation
Jagsonpal Pharmaceuticals Limited has a total of 66.36 Million outstanding shares. Jagsonpal Pharmaceuticals retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 73.66 (percent) of Jagsonpal Pharmaceuticals outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Jagsonpal Pharmaceuticals Profitability Analysis
The company reported the revenue of 2.09 B. Net Income was 224.63 M with profit before overhead, payroll, taxes, and interest of 1.43 B.About Jagsonpal Pharmaceuticals Valuation
An absolute valuation paradigm, as applied to Jagsonpal Stock, attempts to find the value of Jagsonpal Pharmaceuticals based on its fundamental and basic technical indicators. By analyzing Jagsonpal Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Jagsonpal Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Jagsonpal Pharmaceuticals. We calculate exposure to Jagsonpal Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Jagsonpal Pharmaceuticals's related companies.Complementary Tools for Jagsonpal Stock analysis
When running Jagsonpal Pharmaceuticals' price analysis, check to measure Jagsonpal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jagsonpal Pharmaceuticals is operating at the current time. Most of Jagsonpal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jagsonpal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jagsonpal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jagsonpal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |